| Literature DB >> 22157069 |
Henrik Falhammar1, Helena Filipsson Nyström, Urban Ekström, Seth Granberg, Anna Wedell, Marja Thorén.
Abstract
OBJECTIVE: Fertility in males with congenital adrenal hyperplasia (CAH) is reported from normal to severely impaired. Therefore, we investigated fertility/fecundity, social/sexual situation, and pituitary-gonadal function in CAH males. SUBJECTS AND METHODS: The patient cohort comprised 30 males, aged 19-67 years, with 21-hydroxylase deficiency. Their fertility was compared with age-matched national population data. For the evaluation of social/sexual factors and hormone status, age-matched controls were recruited (n = 32). Subgroups of different ages (<30 years and older) and CYP21A2 genotypes (null (severe salt-wasting (SW)), I2splice (milder SW), and I172N (simple virilizing)) were also studied. Patients underwent testicular ultrasound examination (n = 21) and semen analysis (n = 14).Entities:
Mesh:
Substances:
Year: 2011 PMID: 22157069 PMCID: PMC3290120 DOI: 10.1530/EJE-11-0828
Source DB: PubMed Journal: Eur J Endocrinol ISSN: 0804-4643 Impact factor: 6.664
Results of fecundity, fertility, and sexuality evaluations, biochemical tests, and testicle palpation in adult male patients with CAH, also divided into <30 years of age or more and age-matched male controls (mean±s.d. or median and range).
| Age (years) | 35.7±11.4 | 36.5±11.9 | NS | 23.6±3.2 | 24.4±3.3 | NS | 40.9±9.5‡ | 42.0±6.6‡ | NS |
| Fertility and sexuality | |||||||||
| Children ( | 0 (0–5) | 0 (0–4) | NS | 0 (0–1) | 0 (0–1) | NS | 1.0 (0–5)* | 1.5 (1–4)† | NS |
| (0.9±1.3) | (1.0±1.2) | (0.1±0.3) | (0.1±0.3) | (1.2±1.4)* | (1.4±1.3)† | ||||
| Fecundity problems | 6/28 | 1/32 | 0.041 | 2/9 | 0/10 | NS | 4/19 | 1/22 | NS |
| Married/cohabitant | 14/30 | 22/32 | NS | 3/9 | 4/10 | NS | 11/21 | 18/22* | |
| No partner | 11/01 | 8/32 | NS | 5/9 | 5/10 | NS | 7/21 | 3/22§ | NS |
| Partners ( | 3.5 (0–100) | 9.0 (1–50) | 0.038 | 3.8 (0–38) | 3.0 (1–21) | NS | 3.5 (0–100) | 13 (2–50)* | 0.028 |
| Biochemical tests | |||||||||
| FSH (U/l) | 5.2 (1.5–23) | 3.3 (1.6–6.7) | 0.014 | 4.3±2.5 | 2.9±1.2 | NS | 5.2 (1.5–23) | 3.3 (1.6–6.7) | 0.022 |
| Inhibin B (ng/l) | 135±74 | 211±84 | <0.001 | 155±63 | 209±84 | NS | 126±78 | 210±87 | 0.002 |
| LH (U/l) | 3.5 (1.1–22) | 4.3 (1.5–6.2) | NS | 3.6 (1.1–15) | 4.4 (1.5–6.1) | NS | 3.4 (1.2–22) | 4.3 (1.9–6.2) | NS |
| Bioactive testosterone (nmol/l) | 2.3 (0.5–7.7) | 2.6 (1.2–6.7) | 3.6±1.9 | 4.1±1.5 | NS | 1.9±0.9‡ | 2.5±1.2† | ||
| E2 (pmol/l) | 97±50 | 79±25 | 91±45 | 92±36 | NS | 102±53 | 74±18 | 0.024 | |
| Testos/E2 (nmol/pmol) | 0.18±0.09 | 0.22±0.07 | 0.019 | 0.23±0.11 | 0.23±0.09 | NS | 0.15±0.06* | 0.22±0.06 | <0.001 |
| Testicular palpation | |||||||||
| Size (cm3) | 18.1±4.2 | 20.7±3.8 | 0.049 | 18.1±2.9 | 19.1±3.3 | NS | 18.2±5.0 | 21.6±3.9 | |
| Tumors | 2/21 | 0/23 | NS | 1/8 | 0/8 | NS | 1/13 | 0/15 | NS |
*P<0.05, †P<0.01, ‡P<0.001, and §P=0.05–0.099 compared with younger counterparts (patients or controls respectively). NS, non-significant; testos, testosterone; E2, estradiol; F, free; partners, partners during lifetime.
Fecundity problems defined as trying to father a child for >1 year.
Results of fecundity, fertility, and sexuality evaluations, biochemical tests, and testicle palpation in adult male patients with the three most common CYP21A2 genotypes and male controls (mean±s.d. or median and range).
| Age (years) | 34.5±9.5 | NS | 31.6±9.4 | NS | 41.0±14.9 | NS | 36.5±11.9 | NS |
| Fertility and sexuality | ||||||||
| Children ( | 0 (0–3) | NS | 0 (0–3) | NS | 1 (0–5) | NS | 0 (0–4) | NS |
| (1.0±1.3) | (0.58±1.1) | (1.1±1.6) | (1.0±1.2) | |||||
| Fecundity problems | 0/5 | NS | 2/11 | NS | 3/7 | 0.014 | 1/32 | NS |
| Married/cohabitant | 4/7 | NS | 3/11 | 0.031 | 5/8 | NS | 22/32 | NS |
| No partner | 3/7 | NS | 6/11 | NS | 2/8 | NS | 8/32 | NS |
| Partners ( | 1.3±1.5 | 0.031 | 3.0 (0–100) | NS | 4.8 (0–60) | NS | 9.0 (1–50) | |
| Biochemical tests | ||||||||
| FSH (U/l) | 5.2 (1.5–21) | 0.006 | 5.2 (1.8–23) | 0.029 | 3.8 (1.6–12) | 0.049 | 3.3 (1.6–6.7) | NS |
| Inhibin B (ng/l) | 126±63 | 0.019 | 131±102 | 0.016 | 120±42 | 0.004 | 211±84 | NS |
| LH (U/l) | 2.5 (1.2–22) | NS | 5.0±2.7 | NS | 3.4 (1.1–11) | NS | 4.3 (1.5–6.2) | NS |
| Bioactive testosterone (nmol/l) | 2.44 (0.5–7.7) | NS | 1.8 (0.9–5.2) | NS | 2.2 (0.9–3.8) | 2.6 (1.2–6.7) | NS | |
| E2 (pmol/l) | 77 (56–298) | NS | 87±39 | NS | 90±26 | NS | 79±25 | NS |
| Testos/E2 (nmol/pmol) | 0.16±0.09 | 0.21±0.10 | NS | 0.17±0.06 | 0.22±0.07 | NS | ||
| Testicular palpation | ||||||||
| Size (cm3) | 13.5±3.0 | 0.002 | 19.7±3.2 | NS | 18.0±4.8 | NS | 20.7±3.8 | 0.042 |
| Tumors | 2/4 | 0.017 | 0/9 | NS | 0/5 | NS | 0/23 | 0.019 |
NS, non-significant; testos, testosterone; E2, estradiol; F, free.
Fecundity problems defined as trying to father a child for >1 year.
Post-hoc null vs I2splice, P=0.040.
Post-hoc null vs I2splice, P=0.077.
Figure 1Illustration of the steps in the 3D inversion rendering process of right testicle of a 30-year-old male with CAH (genotype null/null) with two children. Acquisition in the three orthogonal planes and the rendered volume in the bottom right box. By eliminating the surrounding non-pertinent structures with the electronic scalpel, the structures of interest were left as the final inverted and rendered volume. In this case, it could be seen that the tumor was calcified and had a cystic structure (right bottom corner, the tumor marked with an arrow). In the left upper box, the tumor is marked with arrows (the size of the tumor was measured to be: 2.6×1.1×0.9 cm, corresponding to a volume of 1.4 cm3). Full colour version of this figure available via http://dx.doi.org/10.1530/EJE-11-0828.
Testicular ultrasound exams and semen samples from adult patients with CAH and the three most common CYP21A2 genotypes (mean±s.d. or median and range).
| Ultrasound | |||||
| Total volume (cm3) | 22.7±7.5 | 18.7±9.0 | 24.6±6.0 | 24.4±11.6 | NS |
| TART present | 18/21 | 4/4 | 8/10 | 4/4 | NS |
| TART ( | 2.0 (0–8) | 2.0 (1–5) | 2 (0–8) | 1.5 (1–2) | NS |
| Total TART (cm3) | 0.5 (0–8.7) | 2.9 (1.9–4.6) | 0.2 (0–8.7) | 0.5 (0.2–4.3) | |
| Total functional (cm3) | 20.4 (7.1–36.7) | 15.6±8.1 | 24.4±5.7 | 23.0±9.8 | NS |
| Semen sample | |||||
| Volume (ml) | 2.3±0.6 | 1.5 | 2.3±0.5 | 2.2±0.6 | NS |
| Sperm count (×106) | 151±112 | 105 | 220±146 | 88±19 | |
| Sperm conc. (×106/ml) | 70±54 | 70 | 99±71 | 44±18 | |
| Motile sperm (%) | 53±21 | 30 | 64±11 | 42±23 | |
| Normal morphology (%) | 3.2±2.8 | 1.0 | 4.5±3.4 | 2.2±1.9 | NS |
| Pathological semen | 6/14 | 1/1 | 3/7 | 2/5 | NS |
NS, non-significant; TART, testicular adrenal rest tumor.
Only one male null/null patient provided a semen sample, thus comparisons were only performed between I2splice and I172N.
Patient characteristics and differences found in body composition, heart rate, blood pressure, and biochemical tests in adult CAH male patients with pathological and normal semen (mean±s.d. or median and range).
| Age (years) | 40.3±15.1 | 35.8±11.2 | NS |
| Phenotype | 4SW/2SV | 4SW/2SV | NS |
| HCeq/m2 (mg/m2) | 18.9±8.4 | 15.4±2.2 | NS |
| BMI (kg/m2) | 29.4±6.3 | 25.3±4.1 | NS |
| Total fat mass (%) | 32.0±8.2 | 24.3±5.7 | 0.049 |
| Truncal fat mass (%) | 35.2±9.7 | 25.9±7.0 | 0.048 |
| Total fat/lean mass | 0.5±0.2 | 0.3±0.1 | 0.032 |
| 24-h BP (mmHg) | 134±6/79±5 | 123±11/74±5 | |
| 24-h heart rate | 81±5 | 73±5 | 0.012 |
| Fecundity problems | 5/6 | 0/8 | 0.003 |
| FSH >10 (U/l) | 2/6 | 0/8 | NS |
| Inhibin B (ng/l) | 157±57 | 167±102 | NS |
| Testosterone (nmol) | 12.5±3.2 | 17.8±6.2 | |
| Testos/E2 (nmol/pmol) | 0.17±0.04 | 0.19±0.07 | NS |
| S-TG (mmol/l) | 1.5±1.0 | 0.9±0.3 |
NS, non-significant; HCeq, hydrocortisone equivalents; TG, triglyceride; BP, blood pressure; testos/E2, testosterone/estradiol ratio.
Fertility problems defined as attempting to father a child for >1 year.
Figure 2Correlation between inhibin B (upper panel), total functional testicular volume (lower panel) and sperm concentration, and total functional testicular volume and inhibin (middle panel) in adult males with CAH due to 21-hydroxylase deficiency.